Day One

• Demonstrating initial clinical feasibility of TIL therapy in colorectal and prostate cancer
• Exploring patient selection and tumor sourcing challenges in low immunogenic indications
• Translating early treatment experience into future trial design decisions

• Presenting pivotal clinical data from patients with advanced melanoma, demonstrating achievement of the study’s primary endpoint and supporting the potential for the first marketed TIL therapy in China
• Exploring innovations in treatment delivery through an IL-2-free regimen, low-intensity pretreatment, and a feeder-free manufacturing process designed to simplify therapy while maintaining clinical efficacy
• Examining outcomes in predominantly acral and mucosal melanoma populations and discussing what these findings could mean for the future evolution of TIL therapy

Join our dedicated networking session to engage in dynamic, fast-paced conversations with fellow industry professionals, exchange insights and expertise, and expand your network within the rapidly evolving TIL therapies landscape. This interactive session will help you foster impactful partnerships and advance innovation across the field.

• Demonstrating clinical feasibility of isolating tumor reactive T-cells across multiple solid tumor types
• Sharing early phase safety and response observations from a selective TIL approach
• Informing future trial design by linking cell composition to clinical outcomes

• Leveraging patient-specific neoantigens to identify and enrich functional tumorreactive T-cells
• Overcoming low frequencies of tumor-reactive lymphocytes in non-melanoma solid tumors
• Establishing a framework for next-generation, precision TIL manufacturing

• Integrating targeted genetic edits to enhance tumor-specific antigen recognition
• Reducing functional exhaustion to support sustained TIL persistence after infusion
• Evaluating how multiplex engineering impacts response durability in solid tumors

• Comparing genome editing approaches used to enhance potency, persistence, and tumor recognition
• Reviewing safety, manufacturability, and regulatory trade-offs of engineered TIL designs
• Identifying where genetic modification adds clear clinical value vs. added complexity
• Can TIL manufacturing be designed for in vivo development rather than culturing the cells in vitro?

• Reprogramming autologous tumor cells into antigen-presenting tumor cells (APTCs) to enable patient-specific antigen presentation without target selection
• Generating polyclonal antigen-specific T cells from peripheral blood to address unresectable and cold solid tumors
• Engineering tumor-specific T cells with intrinsic T-cell modifiers to enhance persistence and overcome tumor-mediated immunosuppression

Contribute to the conversation by sharing your latest research and innovations with the global cell

therapy community and leading experts advancing the future of TIL therapies.

• Establishing CMC quality systems that support consistent TIL manufacturing from early development through commercialization
• Exploring lessons learned from scaling autologous cell therapies from research to industrial manufacturing while maintaining product quality and regulatory compliance
• Navigating global regulatory expectations and integrating manufacturing, quality, and clinical development strategies to accelerate TIL therapy approval and commercialization

• Optimizing manufacturing processes to increase cell dose and scalability while maintaining antigen specificity, functionality, and product quality throughout clinical development
• Ensuring product comparability as manufacturing processes evolve from early clinical studies to larger trials without compromising the biological characteristics that drive therapeutic activity
• Reducing regulatory and scale-up risk by establishing robust, reproducible manufacturing strategies that support both clinical expansion and future commercial readiness